Specifying the Anti-inflammatory Effects of Ziltivekimab

Inclusion Criteria: * Aged 50 years and older. * Multi-vessel coronary artery disease (defined as CAD-RADS ≥2). * Serum hsCRP level ≥2 mg/L. Exclusion Criteria: * Coronary stents in situ. * Chronic or recent (\<1 month) (serious) infections and/or clinical signs of acute (serious) infection. * History of severe auto-immune diseases, or other (severe) (recurrent or chronic) inflammatory disorders. * Use of preventive systemic antibiotics (antibiotics used to treat latent tuberculosis are exempted). * Stable lipid lowering treatment for less than 4 weeks, including statins, ezetimibe and PCSK9 inhibition. * Untreated latent tuberculosis, active hepatitis B (positive HBsAg and/or positive anti-HBc with detectable HBV DNA) or C, human immunodeficiency virus (HIV) not on stable antiretroviral regimen * Uncontrolled diabetes (HbA1c \>90 mmol/mol). * Renal insufficiency, defined as eGFR \<45 ml/min/1.73 m2. * Platelet count \<120,000 and \>450,000 /mm3. * Elevated liver enzymes (\>3 ULN of liver transaminases), acute liver failure or known (severe) liver disease. * Premenopausal women not using birth-control. * History of gastrointestinal perforation, active diverticulitis (within 5 years) or active inflammatory bowel disease (within 12 months). * Uncontrolled hypertension (systolic \>180 mmHg; diastolic \>110 mmHg). * Diagnosis of (active) malignancy in last 5 years. * Standard contra-indications to 68Ga-DOTATATE PET, and CT based on physician's experience and current practices. * Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.